INVENTPRISE
Inventprise is a biotechnology company specializing in GMP vaccine product development. Its vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. The company was founded in 2012 and is headquartered in Redmond, Washington.
INVENTPRISE
Industry:
Biotechnology Health Care Medical
Founded:
2012-01-01
Address:
Redmond, Washington, United States
Country:
United States
Website Url:
http://www.inventprise.com
Total Employee:
101+
Status:
Active
Contact:
(+1) 206-258-2660
Email Addresses:
[email protected]
Total Funding:
90 M USD
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail Frontier Communications
Similar Organizations
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Inventprise
Official Site Inspections
http://www.inventprise.com Semrush global rank: 4.37 M Semrush visits lastest month: 2.58 K
Unable to get host informations!!!
More informations about "Inventprise" on Search Engine
About Us - Inventprise
Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally. MEET OUR TEAM. Our mission is to empower people to live …See details»
Home - Inventprise
We are bringing a new generation of vaccines to empower people everywhere to live healthy lives. LEARN MORE We are bringing a new generation of vaccines to empower people everywhere to live healthy lives. LEARN MORE A Better Vaccine: IVT PCV-25 Our lead candidate, Pneumococcal Conjugate Vaccine for Paediatric, leverages the Inventprise …See details»
Inventprise - Crunchbase Company Profile & Funding
Details. Inventprise is a biotechnology company specializing in GMP vaccine product development. Its vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries.See details»
Inventprise | LinkedIn
By developing novel and affordable vaccines for all populations worldwide we're addressing health inequalities and empowering people to live healthy lives Inventprise is a mission driven vaccine...See details»
Inventprise Receives $30M, Appoints New CEO and Expands …
Redmond, WA (April 7, 2022) – Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced today that it has received $30 million from the Bill & Melinda Gates Foundation’s Strategic Investment Fund, representing the first tranche of up to $90 million in financing secured late last year.See details»
Inventprise Announces Investment of up to $90 Million to …
Nov 10, 2021 Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases, with an initial focus on invasive pneumococcal disease.See details»
Seattle-area startup Inventprise gets backing from Gates
Nov 10, 2021 (Inventprise Photo) The foundation will provide up to $90 million for phase 1 and 2 trials of the vaccine, dependent on Inventprise meeting development and manufacturing milestones. Pneumonia...See details»
Inventprise - Funding, Financials, Valuation & Investors
Inventprise is funded by Bill & Melinda Gates Foundation. Which investors participated in the most funding rounds? Show. Unlock even more features with Crunchbase Pro. Start Your Free Trial. Inventprise is a biotechnology company specializing in GMP vaccine product development.See details»
Inventprise Completes Vaccination of Participants in a Phase 2 …
Jan 2, 2024 About Inventprise Inc. Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive...See details»
New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical ...
Nov 10, 2022 Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, affordable and highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving...See details»
Inventprise Inaugurates Manufacturing Facility for High-Capacity …
May 10, 2022 Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.See details»
Inventprise Announces Investment of up to $90 Million to …
Redmond, WA (November 10, 2021, 2022) –Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced today that the Bill & Melinda Gates Foundation, a global non-profit organization, has made a program-related investment in the company’s continued development of IVT-25, an investigational ...See details»
Inventprise - Gates SIF
Inventprise. Our portfolio. Next-generation pneumococcal conjugate vaccine development for LMICs. Inventprise is developing efficacious, affordable vaccines for global populations most in need.See details»
Inventprise Completes Vaccination of Participants in a Phase 2 …
Jan 2, 2024 Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, affordable and highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally, including to low and middle-income countries.See details»
Inventprise Announces Investment of up to $90 Million to …
Nov 10, 2021 Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced today that the Bill & Melinda Gates Foundation, a global non-profit organization, has made a program-related investment in the company’s continued development of IVT-25, an investigational pneumococcal conjugate vaccine …See details»
Multi-valent pneumococcal conjugate vaccine for global health: …
Nov 30, 2022 Inventprise 25-valent pneumococcal conjugate vaccine candidate with the patented Hz-PEG-Hz linker technology platform is expected to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by populations regardless of where they live.See details»
Inventprise Inaugurates Manufacturing Facility for High
May 10, 2022 REDMOND, Wash.-- ( BUSINESS WIRE )-- Inventprise, a biotechnology company specializing in novel, affordable and impactful vaccines, today announced the inauguration of its new manufacturing facility for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine (IVT-PCV-25) for low- and middle-income countries.See details»
News & Publications - Inventprise
Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board April 7, 2022 Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical TrialsSee details»
New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical ...
Nov 10, 2022 Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, affordable and highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally, including to low and middle-income countries.See details»
Inventprise opens Washington pneumococcal vaccine plant
May 10, 2022 Inventprise, a firm that specializes in affordable vaccines and is supported by the Bill & Melinda Gates Foundation (BMGF), has announced the inauguration of its manufacturing facility intended for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine (IVT-PCV-25) for distribution to low-and-middle-income countries.See details»